Facebook
Twitter
Telegram
Report an ErrorAmphastar Pharmaceuticals Balance Sheet 2011-2024 | AMPH
Annual Balance Sheet Amphastar Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
463 M | -80.3 M | -48.8 M | -57 M | -26.6 M | -36.1 M | -18.4 M | -34.6 M | -25 M | -24.1 M | -21.4 M | -12.2 M | - |
Long Term Debt |
603 M | 72.8 M | 74.8 M | 34.2 M | 39.4 M | 32 M | 40.8 M | 32.4 M | 30.2 M | 36.1 M | 10.1 M | 16 M | - |
Long Term Debt Current |
3.91 M | 3 M | 2.98 M | 3.36 M | 3.18 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 69.4 M | 42.4 M | 50.1 M | 37.9 M | 34.7 M | 44.9 M | 21.8 M | 24 M | - |
Total Current Liabilities |
225 M | 94.9 M | 104 M | 112 M | 90 M | 107 M | 67.2 M | 60.6 M | 60 M | 62.6 M | - | - | - |
Total Liabilities |
873 M | 213 M | 226 M | 183 M | 159 M | 149 M | 117 M | 98.5 M | 94.6 M | 108 M | 87.2 M | 84 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 643 K | 14 M | 643 K | 642 K | - |
Retained Earnings |
409 M | 272 M | 180 M | 118 M | 116 M | 67.5 M | 76.2 M | 70.9 M | 60.3 M | 63.1 M | 73.8 M | 61.9 M | - |
Total Assets |
1.51 B | 742 M | 672 M | 631 M | 587 M | 514 M | 455 M | 428 M | 390 M | 389 M | 339 M | 317 M | - |
Cash and Cash Equivalents |
144 M | 156 M | 127 M | 94.5 M | 73.7 M | 86.3 M | 65.6 M | 72.4 M | 66.1 M | 67.8 M | 53.6 M | 50.2 M | - |
Book Value |
639 M | 529 M | 446 M | 449 M | 428 M | 364 M | 337 M | 329 M | 296 M | 282 M | 252 M | 233 M | - |
Total Shareholders Equity |
639 M | 529 M | 446 M | 449 M | 381 M | 332 M | 337 M | 329 M | 296 M | 282 M | 252 M | 233 M | - |
All numbers in USD currency
Quarterly Balance Sheet Amphastar Pharmaceuticals
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
653 M | 72.9 M | 72.8 M | - | 73.9 M | 74.3 M | 74.8 M | 75.6 M | 30.5 M | 32.3 M | 45.9 M | 34.2 M | 34.2 M | 34.2 M | 46.3 M | 39.4 M | 39.4 M | 39.4 M | 49.1 M | 32 M | 32 M | 32 M | 45.7 M | 40.8 M | 40.8 M | 40.8 M | 36 M | 32.4 M | 32.4 M | 32.4 M | 40.3 M | 30.2 M | 30.2 M | 30.2 M | 42.7 M | 36.1 M | 36.1 M | 36.1 M | 10.1 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
949 M | 225 M | 213 M | - | 224 M | 237 M | 226 M | 222 M | 199 M | 195 M | 183 M | 183 M | 183 M | 183 M | 159 M | 159 M | 159 M | 159 M | 149 M | 149 M | 149 M | 149 M | 117 M | 117 M | 117 M | 117 M | 98.5 M | 98.5 M | 98.5 M | 98.5 M | 94.6 M | 94.6 M | 94.6 M | 94.6 M | 108 M | 108 M | 108 M | 108 M | 87.2 M | 87.2 M | 87.2 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 830 K | 1.66 M | 643 K | 643 K | 643 K | 643 K | 643 K | 14 M | 14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
373 M | 298 M | 272 M | - | 222 M | 205 M | 180 M | 161 M | 131 M | 123 M | 118 M | 118 M | 118 M | 118 M | 116 M | 116 M | 116 M | 116 M | 67.5 M | 67.5 M | 67.5 M | 67.5 M | 72.6 M | 72.6 M | 76.2 M | 76.2 M | 70.9 M | 70.9 M | 70.9 M | 70.9 M | 60.3 M | 60.3 M | 60.3 M | 60.3 M | 63.1 M | 63.1 M | 63.1 M | 63.1 M | 73.8 M | 73.8 M | 73.8 M | - | - | - | - | - | - | - | - | - |
Total Assets |
1.54 B | 774 M | 742 M | - | 724 M | 716 M | 672 M | 652 M | 666 M | 646 M | 631 M | 631 M | 631 M | 631 M | 587 M | 587 M | 587 M | 587 M | 514 M | 514 M | 514 M | 514 M | 451 M | 451 M | 455 M | 455 M | 428 M | 428 M | 428 M | 428 M | 390 M | 390 M | 390 M | 390 M | 389 M | 389 M | 389 M | 389 M | 339 M | 339 M | 339 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
267 M | 177 M | 156 M | 157 M | 166 M | 173 M | 126 M | 107 M | 125 M | 102 M | 94.5 M | 92.6 M | 92.6 M | 92.6 M | 73.7 M | 73.7 M | 73.7 M | 73.7 M | 86.3 M | 86.3 M | 86.3 M | 86.3 M | 65.6 M | 65.6 M | 65.6 M | 65.6 M | 72.4 M | 72.4 M | 72.4 M | 72.4 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 67.8 M | 67.8 M | 67.8 M | 67.8 M | 53.6 M | 53.6 M | 53.6 M | - | 50.2 M | - | - | - | 53.7 M | - | - | - |
Book Value |
595 M | 549 M | 529 M | - | 499 M | 480 M | 446 M | 430 M | 467 M | 451 M | 449 M | 449 M | 449 M | 449 M | 428 M | 428 M | 428 M | 428 M | 364 M | 364 M | 364 M | 364 M | 334 M | 334 M | 337 M | 337 M | 329 M | 329 M | 329 M | 329 M | 296 M | 296 M | 296 M | 296 M | 282 M | 282 M | 282 M | 282 M | 252 M | 252 M | 252 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
595 M | 549 M | 529 M | 505 M | 499 M | 480 M | 446 M | 430 M | 467 M | 451 M | 449 M | 402 M | 402 M | 402 M | 381 M | 381 M | 381 M | 381 M | 332 M | 332 M | 332 M | 332 M | 334 M | 334 M | 337 M | 337 M | 329 M | 329 M | 329 M | 329 M | 296 M | 296 M | 296 M | 296 M | 282 M | 282 M | 282 M | 282 M | 252 M | 252 M | 252 M | - | 233 M | - | - | - | 209 M | - | - | - |
All numbers in USD currency